Buprenorphine alone and in combination with naloxone in non-dependent humans

Linda L. Weinhold; Kenzie L. Preston; Magi Farre; Ira A. Liebson; George E. Bigelow

doi:10.1016/0376-8716(92)90061-G

Buprenorphine alone and in combination with naloxone in non-dependent humans

Linda L. Weinhold, Kenzie L. Preston, Magi Farre, Ira A. Liebson, George E. Bigelow

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

Original language	English (US)
Pages (from-to)	263-274
Number of pages	12
Journal	Drug and alcohol dependence
Volume	30
Issue number	3
DOIs	https://doi.org/10.1016/0376-8716(92)90061-G
State	Published - Aug 1992
Externally published	Yes

Keywords

abuse liability
buprenorphine
human
naloxone
opioid

ASJC Scopus subject areas

Toxicology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1016/0376-8716(92)90061-G

Cite this

@article{e97766019466423cae5fb96de54782d2,

title = "Buprenorphine alone and in combination with naloxone in non-dependent humans",

abstract = "This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.",

keywords = "abuse liability, buprenorphine, human, naloxone, opioid",

author = "Weinhold, {Linda L.} and Preston, {Kenzie L.} and Magi Farre and Liebson, {Ira A.} and Bigelow, {George E.}",

note = "Funding Information: Supported by Reckitt and Colman, Pharmaceutical Division and by USPHS research grant DA-04089, training grant DA-07209 and research Scientist Award DA-00050.",

year = "1992",

month = aug,

doi = "10.1016/0376-8716(92)90061-G",

language = "English (US)",

volume = "30",

pages = "263--274",

journal = "Drug and alcohol dependence",

issn = "0376-8716",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Buprenorphine alone and in combination with naloxone in non-dependent humans

AU - Weinhold, Linda L.

AU - Preston, Kenzie L.

AU - Farre, Magi

AU - Liebson, Ira A.

AU - Bigelow, George E.

N1 - Funding Information: Supported by Reckitt and Colman, Pharmaceutical Division and by USPHS research grant DA-04089, training grant DA-07209 and research Scientist Award DA-00050.

PY - 1992/8

Y1 - 1992/8

N2 - This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

AB - This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

KW - abuse liability

KW - buprenorphine

KW - human

KW - naloxone

KW - opioid

UR - http://www.scopus.com/inward/record.url?scp=0026658251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026658251&partnerID=8YFLogxK

U2 - 10.1016/0376-8716(92)90061-G

DO - 10.1016/0376-8716(92)90061-G

M3 - Article

C2 - 1396108

AN - SCOPUS:0026658251

SN - 0376-8716

VL - 30

SP - 263

EP - 274

JO - Drug and alcohol dependence

JF - Drug and alcohol dependence

IS - 3

ER -

Buprenorphine alone and in combination with naloxone in non-dependent humans

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this